Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aligos Therapeutics, Inc. (ALGS)
:ALGS
RESEARCH TOOLSreports
Holding ALGS?
Track your performance easily
ALGS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.76 - $46.80
Previous CloseN/A
Volume178.18K
Average Volume (3M)431.23K
Market Cap
$113.41M
Enterprise Value-$11.58M
Total Cash (Recent Filing)$90.85M
Total Debt (Recent Filing)$12.61M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Mar 06, 2025EPS Estimate
-2.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.35
Shares Outstanding3,464,199
10 Day Avg. Volume383,208
30 Day Avg. Volume431,230
Standard Deviation0.37
R-Squared0.10
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)18.97
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.10
Enterprise Value/Revenue-2.04
Enterprise Value/Gross Profit-1.87
Enterprise Value/Ebitda0.11
Forecast
1Y Price Target
$125.00Price Target Upside295.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Aligos Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALGS FAQ
What was Aligos Therapeutics, Inc.’s price range in the past 12 months?
Aligos Therapeutics, Inc. lowest stock price was $6.76 and its highest was $46.80 in the past 12 months.
What is Aligos Therapeutics, Inc.’s market cap?
Aligos Therapeutics, Inc.’s market cap is $113.41M.
When is Aligos Therapeutics, Inc.’s upcoming earnings report date?
Aligos Therapeutics, Inc.’s upcoming earnings report date is Mar 06, 2025 which is in 47 days.
How were Aligos Therapeutics, Inc.’s earnings last quarter?
Aligos Therapeutics, Inc. released its earnings results on Nov 06, 2024. The company reported -$3.07 earnings per share for the quarter, missing the consensus estimate of -$2.157 by -$0.913.
Is Aligos Therapeutics, Inc. overvalued?
According to Wall Street analysts Aligos Therapeutics, Inc.’s price is currently Undervalued.
Does Aligos Therapeutics, Inc. pay dividends?
Aligos Therapeutics, Inc. does not currently pay dividends.
What is Aligos Therapeutics, Inc.’s EPS estimate?
Aligos Therapeutics, Inc.’s EPS estimate is -2.5.
How many shares outstanding does Aligos Therapeutics, Inc. have?
Aligos Therapeutics, Inc. has 3,464,199 shares outstanding.
What happened to Aligos Therapeutics, Inc.’s price movement after its last earnings report?
Aligos Therapeutics, Inc. reported an EPS of -$3.07 in its last earnings report, missing expectations of -$2.157. Following the earnings report the stock price went up 6.096%.
Which hedge fund is a major shareholder of Aligos Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ALGS
---
Aligos Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$125.00 (295.44% Upside)
$125.00 (295.44% Upside)
Hedge Fund Trend
Increased
By 11.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 10.0%
Last 30 Days ▲ 10.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
98.49%
12-Months-Change
Fundamentals
Return on Equity
-146.69%
Trailing 12-Months
Asset Growth
3.00%
Trailing 12-Months
Company Description
Aligos Therapeutics, Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).
---
ALGS Stock 12 Month Forecast
Average Price Target
$125.00
▲(295.44% Upside)
Technical Analysis
AnaptysBio
―
Corvus Pharmaceuticals
―
Fulcrum Therapeutics
―
Mersana Therapeutics
―
Crispr Therapeutics AG
―
Novavax
―
Best Analysts Covering ALGS
1 Year
1 Year Success Rate
7/17 ratings generated profit
1 Year Average Return
+21.28%
assigned a buy rating 2 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of +21.28% per trade.
---